LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U. obesity biotech Metsera marks an aggressive shift ...
Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...
Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U. obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback